The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.